EP4125928A1 - Réduction ou inhibition de lésions oculaires par administration d'hyaluronidase - Google Patents

Réduction ou inhibition de lésions oculaires par administration d'hyaluronidase

Info

Publication number
EP4125928A1
EP4125928A1 EP21782409.3A EP21782409A EP4125928A1 EP 4125928 A1 EP4125928 A1 EP 4125928A1 EP 21782409 A EP21782409 A EP 21782409A EP 4125928 A1 EP4125928 A1 EP 4125928A1
Authority
EP
European Patent Office
Prior art keywords
minutes
hyaluronidase
composition
eye
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21782409.3A
Other languages
German (de)
English (en)
Other versions
EP4125928A4 (fr
Inventor
Steve YOELIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med Progress LLC
Original Assignee
Med Progress LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Progress LLC filed Critical Med Progress LLC
Publication of EP4125928A1 publication Critical patent/EP4125928A1/fr
Publication of EP4125928A4 publication Critical patent/EP4125928A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Definitions

  • the present invention relates to the treatment of loss of vision caused by administration of a hyaluronic acid soft-tissue dermal filler.
  • fillers for augmentation of facial soft tissues in an individual has become one of the most commonly performed aesthetic procedures.
  • soft-tissue filler injection is the second most commonly performed cosmetic procedure following botulinum toxin treatment.
  • the most commercially popular soft-tissue dermal fillers are ones employing hyaluronic acid.
  • the present disclosure provides such a solution for soft-tissue dermal fillers comprising hyaluronic acid.
  • the compositions, devices, methods and uses disclosed herein administer a hyaluronidase to the suprachoroidal space of an eye. Such administration delivers a hyaluronidase into the blood vessels supplying an eye in about 5 minutes or less. This fast delivery of hyaluronidase enables this enzyme to Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration reduce or eliminate the hyaluronic acid causing the vascular occlusion, thereby reducing or eliminating the risk of permanent damage to the eye.
  • aspects of the present specification disclose methods of reducing or eliminating a hyaluronic acid- induced blockage in one or more blood vessels supplying blood to an eye in an individual in need thereof.
  • the disclosed methods comprise administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye.
  • the disclosed methods administer composition comprising a hyaluronidase to a suprachoroidal space of an eye.
  • the disclosed methods administer a composition comprising a hyaluronidase using a delivery system, such as, e.g., a needle and syringe, an ADG needle, or a microinjector.
  • a delivery system such as, e.g., a needle and syringe, an ADG needle, or a microinjector.
  • the disclosed methods can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • aspects of the present specification disclose methods of reducing or inhibiting a vascular occlusion in an eye of an individual in need thereof.
  • the disclosed methods comprise administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid- induced blockage in one or more blood vessels supplying blood to an eye, thereby reducing or inhibiting the vascular occlusion in the eye.
  • the disclosed methods administer composition comprising a hyaluronidase to a suprachoroidal space of an eye.
  • the disclosed methods administer a composition comprising a hyaluronidase using a delivery system, such as, e.g., a needle and syringe, an ADG needle, or a microinjector.
  • a delivery system such as, e.g., a needle and syringe, an ADG needle, or a microinjector.
  • the disclosed methods can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • aspects of the present specification disclose methods of reducing or inhibiting hyaluronic acid- induced loss of vision in an individual in need thereof.
  • the disclosed methods comprise administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye, thereby reducing or inhibiting the hyaluronic acid-induced loss of vision in the individual.
  • the disclosed methods administer a composition comprising a hyaluronidase to a suprachoroidal space of an eye.
  • the disclosed methods administer a composition comprising a hyaluronidase using a delivery system, such as, e.g., a needle and syringe, an ADG needle, or a microinjector.
  • a delivery system such as, e.g., a needle and syringe, an ADG needle, or a microinjector.
  • the disclosed methods can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • a delivery system such as, e.g., a needle and syringe, an ADG needle, or a microinjector, comprising a composition comprising a hyaluronidase.
  • the disclosed delivery system delver a composition comprising a hyaluronidase to a suprachoroidal space of an eye.
  • the disclosed delivery system can administer a composition comprising Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration a hyaluronidase in a single or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • compositions comprising a hyaluronidase.
  • the disclosed uses comprise a composition comprising a hyaluronidase contained in a delivery system, such as, e.g., a needle and syringe, ADG needle, or a microinjector.
  • the disclosed uses comprise a composition comprising a hyaluronidase contained in a suprachoroidal microinjector.
  • the disclosed uses comprise a composition comprising a hyaluronidase contained in an AGD needle.
  • the disclosed uses can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • a delivery system such as, e.g., a needle and syringe, ADG needle, or a microinjector, comprising a composition comprising a hyaluronidase.
  • the disclosed uses comprise a suprachoroidal microinjector comprising a composition comprising a hyaluronidase.
  • the disclosed uses comprise an ADG needle comprising a composition comprising a hyaluronidase.
  • the disclosed uses can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • the disclosed medicament comprises a composition comprising a hyaluronidase contained in a delivery system, such as, e.g., a needle and syringe, ADG needle, or a microinjector.
  • the disclosed medicament comprises a composition comprising a hyaluronidase contained in a suprachoroidal microinjector.
  • the disclosed medicament comprises a composition comprising a hyaluronidase contained in an ADG needle.
  • the disclosed uses can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 50 IU to about 20,000 IU of a hyaluronidase.
  • compositions comprising a hyaluronidase for use in inhibiting hyaluronic acid-induced blockage of one or more blood vessels supplying an eye.
  • a composition comprising a hyaluronidase is contained in a delivery system, such as, e.g., a needle and syringe, ADG needle, or a microinjector.
  • a composition comprising a hyaluronidase is contained in a suprachoroidal microinjector.
  • a composition comprising a hyaluronidase is contained in an ADG needle.
  • the disclosed compositions comprising a hyaluronidase can contain a single- or multi-dose amount ranging from about 50 IU to about 20,000 IU of a hyaluronidase.
  • a delivery system such as, e.g., a needle and syringe, ADG needle, or a microinjector, comprising a composition comprising a hyaluronidase for use in inhibiting hyaluronic acid-induced blockage of one or more blood vessels supplying an eye.
  • a disclosed microinjector is a suprachoroidal microinjector.
  • the disclosed delivery system comprising a Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration composition comprising a hyaluronidase can contain a single- or multi-dose amount ranging from about 50 IU to about 20,000 IU of a hyaluronidase.
  • FIG. 1 is a cross-sectional view of a human eye showing its anatomical parts
  • FIG. 2 illustrates the blood vessels associated with a human eye
  • FIG. 3 is a photograph showing a central retinal artery occlusion
  • FIG. 4 is a photograph showing a branch retinal artery occlusion
  • FIG. 5 illustrates a microinjector
  • FIG. 6A-D illustrates administration of a composition comprising a hyaluronidase to a suprachoroidal space of an eye using a microinjector, with FIG. 6A showing general location of injection site; FIG. 6B showing cross-section of eye at injection site; FIG. 6C showing insertion of microinjector at the level of the suprachoroidal space; and FIG. 6D showing administration of a composition disclosed herein into the suprachoroidal space .
  • Eyes are organs of the visual system that detect light and convert it into electro-chemical impulses in neurons.
  • the eyes are a complex optical system that collects light from the surrounding environment, regulates its intensity through a diaphragm, focuses it through an adjustable assembly of lenses to form an image, converts this image into a set of electrical signals, and transmits these signals to the brain through complex neural pathways that connect the eye via the optic nerve to the visual cortex and other areas of the brain.
  • the major anatomical structures of a human eye are shown in FIG. 1 .
  • FIG. 2 Blood vessels providing ophthalmic circulation to the eye are shown in FIG. 2.
  • the central retinal artery, the short- and long-posterior ciliary arteries, the anterior ciliary arteries, and other arteries, all of which are branches from the ophthalmic artery, provide the arterial supply to the eye.
  • the central retinal Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration artery and the short-posterior ciliary arteries supply blood to the retina.
  • the central retinal artery travels in or beside the optic nerve as the central retinal artery pierces the sclera and then branches to supply the layers of the inner retina with blood.
  • Other branches of the ophthalmic artery provide nutrients to the eye and its muscles.
  • Hyaluronidases are a family of enzymes that catalyze the degradation of hyaluronic acid.
  • one possible solution to a hyaluronic acid-induced blockage of one or more vessels supplying an eye is to administer a hyaluronidase to this site of blockage.
  • hyaluronidase there is currently no known way to effectively deliver hyaluronidase to the ophthalmic circulation in a manner that would reduce or eliminate hyaluronic acid-induced blockage of the ophthalmic circulation.
  • compositions, devices, methods and uses disclosed herein effectively deliver hyaluronidase to the ophthalmic circulation in a manner that would reduce or eliminate hyaluronic acid-induced blockage to one or more blood vessels supplying an eye.
  • Such reduction or elimination of hyaluronic acid-induced vascular occlusion involves the administration of a hyaluronidase to a suprachoroidal space of an eye.
  • Such administration ultimately delivers a hyaluronidase into the blood vessels supplying an eye in about 90 minutes or less, preferably 60 minutes or less, more preferably 30 minutes or less, and most preferably 5 to 15 minutes or less.
  • This fast delivery of hyaluronidase enables this enzyme to reduce or eliminate the hyaluronic acid causing the vascular occlusion, thereby reducing or eliminating the risk of permanent damage to the eye.
  • a pharmaceutical composition disclosed herein refers to a therapeutically effective concentration of an active ingredient, such as, e.g., a hyaluronidase disclosed herein.
  • the pharmaceutical composition disclosed herein does not produce an adverse, allergic, or other untoward or unwanted reaction when administered to an individual.
  • a pharmaceutical composition disclosed herein is useful for medical and veterinary applications.
  • a pharmaceutical composition disclosed herein may be formulated as a liquid pharmaceutical composition or as a dried pharmaceutical composition, such as, e.g., a lyophilized or freeze-dried formulation.
  • a pharmaceutical composition disclosed herein may be administered alone to an individual or in combination with supplementary active compounds, agents, drugs or hormones.
  • Hyaluronidase hydrolyses hyaluronic acid. According to their enzymatic mechanism, hyaluronidases are hyaluronoglucosidases (EC Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
  • hyaluronidase may also refer to hyaluronoglucuronidases (EC 3.2.1.36), which cleave (1->3)-linkages.
  • Pharmacokinetics of hyaluronidase have been assessed in animal studies after intravitreous injection. The plasma half-life is 49 hours. The highest concentrations are achieved in vitreous, retina, and sclera. The half-life in ocular tissues is between 60 and 112 hours.
  • Hyaluronidase can be commercially obtained from animals, where it is typically extracted from ovine or bovine testicles (Vitrase, Bausch Health Companies, Inc., Laval, Quebec, Canada), leech, or bacteria. Hyaluronidase can also be obtained recombinantly, e.g., by genetically manipulating human recombinant DNA in Chinese hamster ovary cells (Hylenex, Halozyme Therapeutics, Inc., San Diego, CA).
  • a therapeutically effective amount of a hyaluronidase is an amount sufficient to reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye.
  • a therapeutically effective amount of a hyaluronidase is an amount sufficient to reduce one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye or an amount sufficient to protect the individual against one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye.
  • the term “therapeutically effective amount” includes the terms “amount sufficient”, “therapeutically sufficient amount”, “effective amount”, “effective dose”, or “therapeutically effective dose” and refers to the minimum amount of a hyaluronidase necessary to achieve the desired therapeutic effect and includes an amount sufficient to reduce or inhibit one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye.
  • a therapeutically effective amount of a hyaluronidase disclosed herein reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
  • an effective amount of a hyaluronidase disclosed herein reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • an effective amount of a hyaluronidase disclosed herein reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 30% to about 40%, about 40% to
  • an effective amount of a hyaluronidase disclosed herein reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye for, e.g., at least one week, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, or at least twelve months.
  • a therapeutically effective amount of a hyaluronidase disclosed herein restores or maintains one or more qualitative or quantitative aspects of vision by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
  • an effective amount of a hyaluronidase disclosed herein restores or maintains one or more qualitative or quantitative aspects of vision by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • an effective amount of a hyaluronidase disclosed herein restores or maintains one or more qualitative or quantitative aspects of vision by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 100%, about 50% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%,
  • an effective amount of a hyaluronidase disclosed herein restores or maintains one or more qualitative or quantitative aspects of vision for, e.g., at least one week, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, or at least twelve months.
  • the actual therapeutic effective amount of a hyaluronidase disclosed herein to be used or administered to an individual can be determined by a person of ordinary skill in the art by taking into account factors that include, without limitation, the type of hyaluronic acid-induced blockage, the particular physiological conditions or symptoms associated with a hyaluronic acid-induced blockage, the cause of a hyaluronic acid-induced blockage, the severity of a hyaluronic acid-induced blockage, the degree of relief desired for a hyaluronic acid-induced blockage, the duration of relief desired for a hyaluronic acid-induced Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration blockage, the particular soft-tissue dermal filler used, the rate of excretion of the particular hyaluronidase used, the pharmacodynamics of the particular hyaluronidase used, the nature of the other compounds to be included in the therapy, the particular route
  • an effective amount of a hyaluronidase disclosed herein can be extrapolated from in-vitro assays and in-vivo administration studies using animal models prior to administration to humans. Variations in dosage levels can be adjusted using standard empirical routines of optimization, which are well-known to a person of ordinary skill in the art. The precise therapeutically effective dosage levels and patterns are preferably determined by the attending healthcare professional in consideration of the above-identified factors.
  • dosing can be a single-dose administration or multiple-dose administration.
  • concentration of hyaluronidase in a composition disclosed herein is one that effectively reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels of an eye.
  • the total amount of hyaluronidase cumulatively administered by the multiple doses is one that effectively reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels of an eye.
  • a composition disclosed herein can comprising a hyaluronidase in a concentration between about 15 lU/mL and about 20,000 lU/mL.
  • a composition disclosed herein comprises a hyaluronidase in a concentration of, e.g., at least 15 lU/mL, at least 25 lU/mL, at least 50 lU/mL, at least 100 lU/mL, at least 200 lU/mL, at least 300 lU/mL, at least 450 lU/mL, at least 600 lU/mL, at least 900 lU/mL, at least 1 ,000 lU/mL, at least 1 ,250 lU/mL, at least 1 ,500 lU/mL, at least 1 ,750 lU/mL, at least 2,000 lU/mL, at least 3,000 lU/mL, at least 4,000 lU/
  • a composition disclosed herein comprises a hyaluronidase in a concentration of, e.g., at most 15 lU/mL, at most 25 lU/mL, at most 50 lU/mL, at most 100 lU/mL, at most 200 lU/mL, at most 300 lU/mL, at most 450 lU/mL, at most 600 lU/mL, at most 900 lU/mL, at most 1 ,000 lU/mL, at most 1 ,250 lU/mL, at most 1 ,500 lU/mL, at most 1 ,750 lU/mL, at most 2,000 lU/mL, at most 3,000 lU/mL, at most 4,000 lU/mL, at most 5,000 lU/mL, at most 6,000 lU/mL, at most 7,000 lU/mL, at most 8,000 lU/m
  • a composition disclosed herein comprises a hyaluronidase in a concentration of, e.g., about 15 lU/mL to about 25 lU/mL, about 15 lU/mL to about 50 lU/mL, about 15 lU/mL to about 100 lU/mL, about 15 lU/mL to about 200 lU/mL, about 15 lU/mL to about 300 lU/mL, about 15 lU/mL to about 400 lU/mL, about 15 lU/mL to about 450 lU/mL, about 15 lU/mL to about 600 lU/mL, Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration about 15 lU/mL to about 750 lU/mL, about 15 lU/mL to about 900 lU/mL, about 25 lU/mL
  • a composition disclosed herein comprises a hyaluronidase in a concentration of, e.g., about 10,000 lU/mL to about 11 ,000 lU/mL, about 10,000 lU/mLto about 12,000 lU/mL, about 10,000 lU/mL to about 13,000 lU/mL, about 10,000 lU/mL to about 14,000 lU/mL, about 10,000 lU/mL to about 15,000 lU/mL, about 10,000 lU/mL to about 16,000 lU/mL, about 10,000 lU/mL to about 17,000 lU/mL, about 10,000 lU/mL to about 18,000 lU/mL, about 10,000 lU/mL to about 19,000 lU/mL, about 10,000 lU/mL to about 20,000 lU/mL, about 11 ,000 lU/mL to about 12,000 lU/mL,
  • a single-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include between about 15 IU and about 10,000 IU of a hyaluronidase.
  • a single-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid- induced blockage in one or more blood vessels of an eye can include a hyaluronidase in an amount of, e.g., at least 15 IU, at least 25 IU, at least 50 IU, at least 100 IU, at least 200 IU, at least 300 IU, at least 450 IU, at least 600 IU, at least 900 IU, at least 1 ,000 IU, at least 1 ,250 IU, at least 1 ,500 IU, at least 1 ,750 IU, at least 2,000 IU, at least 3,000 IU, at least 4,000 IU, at least 5,000 IU, at least 6,000 IU, at least 7,000 IU, at least 8,000 IU, at least 9,000 IU, or at least 10,000 IU.
  • a singledose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include a hyaluronidase in an amount of, e.g., at most 15 IU, at most 25 IU, at most 50 IU, at most 100 IU, at most 200 IU, at most Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
  • a single-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include a hyaluronidase in an amount of, e.g., about 15 IU to about 25 IU, about 15 IU to about 50 IU, about 15 IU to about 100 IU, about 15 IU to about 200 IU, about 15 IU to about 300 IU, about 15 IU to about 400 IU, about 15 IU to about 450 IU, about 15 IU to about 600 IU, about 15 IU to about 750 IU, about 15 IU to about 900 IU, about 25 IU to about 50 IU, about 25 IU to about 100 IU, about 25 IU to about 200 IU, about 25 IU to about 300 IU, about 25 IU to about 400 IU, about 25 IU to about 450 IU, about 25 IU to about 900 IU, about 25 IU to about
  • all doses of a multi-dose administration occur within, e.g., at least 1 minute, at least 2 minutes, at least 3 minutes, at least 4 minutes, at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 11 minutes, at least 12 minutes, at least 13 minutes, at least 14 minutes, at least 15 minutes, at least 30 minutes, at least 45 minutes, at least 60 minutes, at least 75 minutes or at least 90 minutes.
  • all doses of a multi-dose administration occur within, e.g., at most 2 minutes, at most 3 minutes, at most 4 minutes, at most 5 minutes, at most 6 minutes, at most 7 minutes, at most 8 minutes, at most 9 minutes, at most 10 minutes, at most 11 minutes, at most 12 minutes, at most 13 minutes, at most 14 minutes, at most 15 minutes, at most 30 minutes, at most 45 minutes, at most 60 minutes, at most 75 minutes or at most 90 minutes.
  • all doses of a multi-dose administration occur within, e.g., about 2 to about 3 minutes, about 2 to about 4 minutes, about 2 to about 5 minutes, about 2 to about 6 minutes, about 3 to about 4 minutes, about 3 to about 5 minutes, about 3 to about 6 minutes, about 4 to about 5 minutes, about 4 to about 6 minutes, about 5 to about 6 minutes, about 5 to about 7 minutes, about 5 to about 8 minutes, about 5 to about 9 minutes, about 5 to about 10 minutes, about 5 to about 11 minutes, about 6 to about 7 minutes, about 6 to about 8 minutes, about 6 to about 9 minutes, about 6 to about 10 minutes, about 6 to about 11 minutes, about 7 to about 8 minutes, about 7 to about 9 minutes, about 7 to about 10 minutes, about 7 to about 11 minutes, about 8 to about 9 minutes, about 8 to about 10 minutes, about 8 to about 11 minutes, about 9 to about 10 minutes, about 9 to about 11 minutes, about 10 to about 11 minutes, about 10 to about 12 minutes, about 10 to about 13 minutes, about 10 to about
  • the number of doses administered in a multi-dose administration is from, e.g., about 2 to about 5 minutes, about 2 to about 10 minutes, about 2 to about 15 minutes, about 5 to about 10 minutes, about 5 to about 15 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 15 minutes, about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 75 minutes, or about 15 minutes to about 90 minutes.
  • the number of doses administered is the number needed to achieve an effective amount of hyaluronidase in order to reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye.
  • the number of doses administered in a multi-dose administration is, e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration at least 10, at least 11 , at least 12, at least 13, at least 14, or at least 15.
  • the number of doses administered in a multi-dose administration is, e.g., at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11 , at most 12, at most 13, at most 14, or at most 15.
  • the number of doses administered in a multi-dose administration is from, e.g., about 2 to about 3, about 2 to about 4, about 2 to about 5, about 2 to about 6, about 3 to about 4, about 3 to about 5, about 3 to about 6, about 4 to about 5, about 4 to about 6, about 5 to about 6, about 5 to about 7, about 5 to about 8, about 5 to about 9, about 5 to about 10, about 5 to about 11 , about 6 to about 7, about 6 to about 8, about 6 to about 9, about 6 to about 10, about 6 to about 11 , about 7 to about 8, about 7 to about 9, about 7 to about 10, about 7 to about 11 , about 8 to about 9, about 8 to about 10, about 8 to about 11 , about 9 to about 10, about 9 to about 11 , about 10 to about 11 , about 10 to about 11 , about 10 to about 12, about 10 to about 13, about 10 to about 14, about 10 to about 15, about 11 to about 12, about 11 to about 13, about 11 to about 14, about 11 to about 15, about 12 to about 13, about 12 to about 14, about 12 to about 15, about 13 to about 14, about 13 to
  • the number of doses administered in a multi-dose administration is from, e.g., about 2 to about 5, about 2 to about 10, about 2 to about 15, about 5 to about 10, about 5 to about 15, or about 10 to about 15.
  • a multi-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include a total amount of about 15 IU to about 10,000 IU of a hyaluronidase.
  • a multi-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include a total amount of hyaluronidase that is, e.g., at least 15 IU, at least 25 IU, at least 50 IU, at least 100 IU, at least 200 IU, at least 300 IU, at least 450 IU, at least 600 IU, at least 900 IU, at least 1 ,000 IU, at least 1 ,250 IU, at least 1 ,500 IU, at least 1 ,750 IU, at least 2,000 IU, at least 3,000 IU, at least 4,000 IU, at least 5,000 IU, at least 6,000 IU, at least 7,000 IU, at least 8,000 IU, at least 9,000 IU, at least 10,000 IU, at least 11 ,000 IU, at least 12,000 IU, at least 13,000 IU, at least 1
  • a multi-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include a total amount of hyaluronidase that is, e.g., at most 15 IU, at most 25 IU, at most 50 IU, at most 100 IU, at most 200 IU, at most 300 IU, at most 450 IU, at most 600 IU, at most 900 IU, at most 1 ,000 IU, at most 1 ,250 IU, at most 1 ,500 IU, at most 1 ,750 IU, at most 2,000 IU, at most 3,000 IU, at most 4,000 IU, at most 5,000 IU, at most 6,000 IU, at most 7,000 IU, at most 8,000 IU, at most 9,000 IU, or at most 10,000 IU.
  • a multi-dose amount of a composition comprising a hyaluronidase used to effectively reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels of an eye can include a total amount of hyaluronidase that is, e.g., about 15 IU to about 25 IU, about 15 IU to about 50 IU, about 15 IU to about 100 IU, about 15 IU to about 200 IU, about 15 IU to about 300 IU, about 15 IU to about 400 IU, about 15 IU to about 450 IU, about 15 IU to about 600 IU, about
  • IU about 25 IU to about 200 IU, about 25 IU to about 300 IU, about 25 IU to about 400 IU, about 25 IU to about 450 IU, about 25 IU to about 600 IU, about 25 IU to about 750 IU, about 25 IU to about 900 IU, about 50 IU to about 100 IU, about 50 IU to about 200 IU, about 50 IU to about 300 IU, about 50 IU to about 400 IU, about 50 IU to about 450 IU, about 50 IU to about 600 IU, about 50 IU to about 750 IU, about 50 IU to about 900 IU, about 100 IU to about 200 IU, about 100 IU to about 300 IU, about 100 IU to about 400 IU, about 100 IU to about 450 IU, about 100 IU to about 600 IU, about 100 IU to about 750 IU, about 100 IU to about 900 IU, about 100 IU to about 200 IU, about 100 IU to about 300 IU, about 100
  • a composition comprising a hyaluronidase disclosed herein is formulated to rapidly cover the relatively large area of a suprachoroidal space of an eye. Such rapid expansion ensures that sufficient amounts of a hyaluronidase are transported to one or more blood vessels supplying an eye within about 90 minutes or less.
  • a composition comprising a hyaluronidase disclosed herein is formulated to rapidly cover the relatively large area of a suprachoroidal space of an eye in, e.g., at most 15 minutes, at most 30 minutes, at most 45 minutes, at most 60 minutes, at most 75 minutes or at most 90 Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration minutes.
  • a composition comprising a hyaluronidase disclosed herein is formulated to rapidly cover the relatively large area of a suprachoroidal space of an eye in, e.g., about 5 minutes to about 10 minutes, about 5 minutes to about 15 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 15 minutes, about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 75 minutes, or about 15 minutes to about 90 minutes.
  • the rapid expansion ensures that sufficient amounts of a hyaluronidase are transported to one or more blood vessels supplying an eye within about 5 to about 15 minutes or less.
  • a composition comprising a hyaluronidase disclosed herein is formulated to rapidly coverthe relatively large area of a suprachoroidal space of an eye in, e.g., at most 1 minute, at most
  • composition comprising a hyaluronidase disclosed herein is formulated to rapidly coverthe relatively large area of a suprachoroidal space of an eye in, e.g., about 1 minute to about 3 minutes, about 1 minute to about 5 minutes, about 1 minute to about 7 minutes, about 1 minute to about 10 minutes, about 1 minute to about 15 minutes, about 3 minutes to about 5 minutes, about
  • the volume of a composition comprising a hyaluronidase delivered to a suprachoroidal space can range from about 5 pL to about 500 pL.
  • a volume of a composition comprising a hyaluronidase delivered to a suprachoroidal space can be, e.g., at least 5 pL, at least 10 pL, at least 20 pL, at least 30 pL, at least 40 pL, at least 50 pL, at least 75 pL, at least 100 pL, at least 200 pL, at least 300 pL, at least 400 pL, or at least 500 pL.
  • a volume of a composition comprising a hyaluronidase delivered to a suprachoroidal space can be, e.g., at most 5 pL, at most 10 pL, at most 20 pL, at most 30 pL, at most 40 pL, at most 50 pL, at most 75 pL, at most 100 pL, at most 200 pL, at most 300 pL, at most 400 pL, or at most 500 pL.
  • a volume of a composition comprising a hyaluronidase delivered to a suprachoroidal space can be, e.g., about 5 pL to about 25 pL, about 5 pL to about 50 pL, about 5 pL to about 75 pL, about 5 pL to about 100 pL, about 10 pL to about 25 pL, about 10 pL to about 50 pL, about 10 pL to about 75 pL, about 10 pL to about 100 pL, about 25 pL to about 50 pL, about 25 pL to about 75 pL, about 25 pL to about 100 pL, about 25 pL to about 150 pL, about 50 pL to about 75 pL, about 50 pL to about 100 pL, about 50 pL to about 150 pL, about 50 pL to about 75 pL, about 50 pL to about 100 pL, about 50 pL to about 150 pL, about 50
  • Non-limiting examples of a delivery system include such as, e.g., a needle and syringe, ADG needle, an ADG-like needle, or a microinjector.
  • Non-limiting examples, of needle gauged useful for a delivery system such as, e.g., a needle and syringe, ADG needle, an ADG-like needle, or a microinjector, include 21 gauge, 22 gauge, 23 gauge, 24 gauge, 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, 30 gauge, 31 gauge, 32 gauge, and 33 gauge.
  • microinjector includes a suprachoroidal microinjector.
  • a composition comprising a hyaluronidase disclosed herein can be administered to a suprachoroidal space of an eye using a microinjector (FIG. 5).
  • microinjectors are commercially available and include, without limitation, a SCSTM Microinjector (Clearside Biomedical Inc., Alpharetta, GA).
  • a suprachoroidal space is the space between the choroid and the sclera that traverses the circumference of the posterior segment of an eye.
  • a suprachoroidal space facilitates easy access to the choroid, retinal pigment epithelium, and retina.
  • Suprachoroidal dosing of a composition comprising a hyaluronidase for the treatment of ophthalmic vascular occlusion has several potential advantages, including high bioavailability as well as differentiating efficacy and safety.
  • Suprachoroidal administration gives access to posterior tissues of the eye. As shown in FIGS. 6A-D, suprachoroidally injected fluids rapidly cover a relatively large area, as much as a few square centimeters, within a few seconds of administration.
  • hyaluronidase distribution is predominantly in the retina and choroid with low amounts of the enzyme entering in the anterior segment of the eye, resulting in lower incidence of IOP (intraocular pressure) increases and cataract formation.
  • Suprachoroidal administration is also an attractive route of hyaluronidase delivery because it allows for the bypassing of the sclera without the risk of intraocular penetration. Besides keeping systemic levels of hyaluronidase low, suprachoroidal administration also facilitates using lower amounts of hyaluronidase when compared to intravitreal or other ophthalmic delivery routes.
  • aspects of the present specification disclose methods of reducing or eliminating a hyaluronic acid- induced blockage in one or more blood vessels supplying blood to an eye.
  • the disclosed methods comprise administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye.
  • the disclosed methods administer composition comprising a hyaluronidase to a suprachoroidal space of an eye.
  • the disclosed methods administer a composition comprising a hyaluronidase using a delivery system disclosed herein.
  • the disclosed methods can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration least 80%, at least 90% or at least 95% or more.
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid- induced blockage in one or more blood vessels of an eye by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 40%, about 40% to
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye for, e.g., at least one week, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, or at least twelve months.
  • aspects of the present specification disclose methods of reducing or inhibiting a vascular occlusion in an eye of an individual in need thereof.
  • a vascular occlusion is reduced or inhibited by reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to the eye.
  • the disclosed methods comprise administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye, thereby reducing or inhibiting the vascular occlusion in the eye.
  • the disclosed methods administer composition comprising a hyaluronidase to a suprachoroidal space of an eye.
  • the disclosed methods administer a composition comprising a hyaluronidase using a microinjector.
  • the disclosed methods can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • reducing or inhibiting a vascular occlusion in an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., at least 10%, at least 20%, at least 30%, at least Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
  • reducing or inhibiting a vascular occlusion in an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • reducing or inhibiting a vascular occlusion in an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about
  • reducing or inhibiting a vascular occlusion in an eye reduces or inhibits one or more physiological conditions or symptoms associated with a hyaluronic acid-induced blockage in one or more blood vessels of an eye for, e.g., at least one week, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, or at least twelve months.
  • aspects of the present specification disclose methods of reducing or inhibiting hyaluronic acid- induced loss of vision in an individual in need thereof.
  • a hyaluronic acid-induced loss of vision is reduced or inhibited by reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye.
  • the disclosed methods comprise administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye, thereby reducing or inhibiting the hyaluronic acid- induced loss of vision in the individual.
  • the disclosed methods administer a composition comprising a hyaluronidase to a suprachoroidal space of an eye. In other aspects, the disclosed methods administer a composition comprising a hyaluronidase using a delivery system disclosed herein. The disclosed methods can administer a composition comprising a hyaluronidase in a single- or multi-dose amount ranging from about 15 IU to about 10,000 IU of a hyaluronidase.
  • the methods disclosed herein comprise multiple doses of a hyaluronidase
  • such administrations can occur in rapid succession.
  • 3 to 20 doses of a composition comprising a hyaluronidase can be administered to the same eye within 5 to 15 minutes.
  • 5 to 15 doses of a composition comprising a Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration hyaluronidase can be administered to the same eye within 5 to 15 minutes.
  • 7 to 15 doses of a composition comprising a hyaluronidase can be administered to the same eye within 5 to 15 minutes.
  • 8 to 12 doses of a composition comprising a hyaluronidase can be administered to the same eye within 5 to 15 minutes.
  • 10 doses of a composition comprising a hyaluronidase can be administered to the same eye within 5 to 15 minutes.
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye restores or maintains one or more qualitative or quantitative aspects of vision by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye restores or maintains one or more qualitative or quantitative aspects of vision by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye restores or maintains one or more qualitative or quantitative aspects of vision by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 100%, about 50% to about 90%, about 40% to about 80%,
  • reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye restores or maintains one or more qualitative or quantitative aspects of vision for, e.g., at least one week, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, or at least twelve months.
  • composition comprising a hyaluronidase can be administered to the suprachoroidal space.
  • a delivery system depicted as a microinjector, is position over a portion of the sclera with the device perpendicular to the surface of the injection site.
  • the device is then pressed against the scleral surface to create a “dimple” around the hub of the delivery system. As shown in FIG.
  • the needle of the delivery system is then inserted through the scleral layer and into the suprachoroidal space, and the plunger of the device is depressed gently while maintaining the dimple on the eye surface for 3-5 seconds to completely administer Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration the hyaluronidase into the suprachoroidal space. Administration can be completed with one or two hands, depending on the user’s preference.
  • the methods disclosed herein reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye. In some embodiments, the methods disclosed herein reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye within a timeframe that prevents, reduces or stops loss of vision or other organ or tissue damage.
  • the methods disclosed herein reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye within about 90 minutes or less.
  • a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye is reduced or eliminated in, e.g., at most 15 minutes, at most 30 minutes, at most 45 minutes, at most 60 minutes, at most 75 minutes or at most 90 minutes.
  • a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye is reduced or eliminated in, e.g., about 5 minutes to about 10 minutes, about 5 minutes to about 15 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 15 minutes, about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 75 minutes, about 15 minutes to about 90 minutes.
  • the methods disclosed herein reduce or eliminate a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye within about 5 to about 15 minutes or less.
  • a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye is reduced or eliminated in, e.g., at most 1 minute, at most 2 minutes, at most 3 minutes, at most 4 minutes, at most 5 minutes, at most 10 minutes, or at most 15 minutes.
  • a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye is reduced or eliminated in, e.g., about 1 minute to about 3 minutes, about 1 minute to about 5 minutes, about 1 minute to about 7 minutes, about 1 minute to about 10 minutes, about 1 minute to about 15 minutes, about 3 minutes to about 5 minutes, about 3 minutes to about 7 minutes, about 3 minutes to about 10 minutes, about 3 minutes to about 15 minutes, about 5 minutes to about 7 minutes, about 5 minutes to about 10 minutes, about 5 minutes to about 15 minutes, or about 10 minutes to about 15 minutes.
  • kits can comprise a container that includes a composition comprising a hyaluronidase disclosed herein.
  • a kit can comprise a plurality of containers, with each such container including a composition comprising a hyaluronidase disclosed herein.
  • a kit can comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more containers, with each such container including a composition comprising a hyaluronidase disclosed herein.
  • Each of the disclosed containers can comprise a single dose of a composition comprising a hyaluronidase disclosed herein, multiple doses of a composition comprising a hyaluronidase disclosed herein, or a combination thereof.
  • each of the disclosed containers can contain a composition comprising a hyaluronidase disclosed herein in liquid form or in dried form.
  • a container disclosed herein can be a vial or similar vessel containing a composition comprising a hyaluronidase disclosed herein, where such composition comprising a hyaluronidase disclosed herein would need to be transferred to a delivery system, such as, e.g., a needle and syringe, ADG needle, or a microinjector.
  • a delivery system such as, e.g., a needle and syringe, ADG needle, or a microinjector.
  • a kit can comprise one or more vials, e.g., 7 to 15 vials or 8 to 12 vials or 10 vials, with each such vial containing a composition comprising a hyaluronidase disclosed herein and optionally one or more delivery systems, e.g., 7 to 15 delivery systems or 8 to 12 delivery systems or 10 delivery systems, with each such delivery system employed to deliver the disclosed compositions when needed.
  • vials e.g., 7 to 15 vials or 8 to 12 vials or 10 vials
  • delivery systems e.g., 7 to 15 delivery systems or 8 to 12 delivery systems or 10 delivery systems
  • a container disclosed herein can be a delivery system containing a composition comprising a hyaluronidase disclosed herein.
  • a kit can comprise one or more delivery systems, e.g., 7 to 15 delivery systems or 8 to 12 delivery systems or 10 delivery systems, with each such delivery system containing a composition comprising a hyaluronidase disclosed herein.
  • a kit can comprise one or more microinjectors, e.g., 7 to 15 microinjectors or 8 to 12 microinjectors or 10 microinjectors, with each such microinjector containing a composition comprising a hyaluronidase disclosed herein.
  • a kit can comprise one or more ADG needles, e.g., 7 to 15 ADG needles or 8 to 12 ADG needles or 10 ADG needles, with each such ADG needle containing a composition comprising a hyaluronidase disclosed herein.
  • kits disclosed herein can comprise other components.
  • a kit disclosed herein can further include containers comprising a solvent, such as, e.g., water or a buffered solution, e.g. saline.
  • a solvent disclosed herein is useful to reconstitute a dried pharmaceutical composition disclosed herein.
  • a kit disclosed herein can comprise a delivery system.
  • the delivery system of the kit is useful for applying a composition disclosed herein to a site of interest, e.g., a suprachoroidal space disclosed herein.
  • a delivery or application system disclosed herein includes, without limitation, one or more needles, syringes, ADG needles, and/or microinjectors.
  • a kit comprises a single delivery system.
  • a kit comprises a plurality of delivery systems.
  • each kit can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more delivery systems.
  • the delivery system may be packaged individually or in sets of 2 or more.
  • the delivery system can be packaged such that it remains sterile until use.
  • a delivery system disclosed herein can be packaged in plastic sheaths.
  • a delivery system disclosed herein is preferably a single-use, disposable delivery system.
  • the kit can also comprise a set of instructions.
  • the instructions may include information useful to the end user such as, e.g., how to use a delivery system to apply a composition disclosed herein and/or how often to apply a composition disclosed herein.
  • such instructions may include information regarding howto mix a solvent disclosed herein to reconstitute a dried composition disclosed herein. Such instructions can indicate that mixing should be done at a certain time before application, e.g., just prior to use.
  • Instructions disclosed herein may also include information regarding how to apply a composition Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration disclosed herein directly to a site of interest, e.g., a suprachoroidal space disclosed herein, and in what order or timing the composition disclosed herein should be applied to such sites of interest.
  • kits including a container, a composition, a delivery system, and instructions disclosed herein, are enclosed in an outer casing.
  • the outer casing can be a box, a sealed bag, a foil pouch, etc.
  • the delivery system, container and instructions are enclosed in a box.
  • the container and instructions are contained in a first box, the delivery system is contained in a second box, and the first and second boxes are contained together in a third box.
  • a method of reducing or eliminating a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye in an individual in need thereof comprising administering a composition comprising a hyaluronidase to the individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye.
  • a method of reducing or inhibiting a vascular occlusion in an eye of an individual in need thereof comprising administering a composition comprising a hyaluronidase to the individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye, thereby reducing or inhibiting the vascular occlusion in the eye.
  • a method of reducing or inhibiting a hyaluronic acid-induced loss of vision in an individual in need thereof comprising administering a composition comprising a hyaluronidase to an individual in a manner that reduces or eliminates a hyaluronic acid-induced blockage in one or more blood vessels supplying blood to an eye, thereby reducing or inhibiting the hyaluronic acid-induced loss of vision in the individual.
  • composition is administered to a suprachoroidal space of the eye.
  • composition comprises the hyaluronidase in a concentration of at least 15 lU/mL, at least 25 lU/mL, at least 50 lU/mL, at least 100 lU/mL, at least 200 lU/mL, at least 300 lU/mL, at least 450 lU/mL, at least 600 lU/mL, at least 900 lU/mL, at least 1 ,000 lU/mL, at least 1 ,250 lU/mL, at least 1 ,500 lU/mL, at least 1 ,750 lU/mL, at least 2,000 lU/mL, at least 3,000 lU/mL, at least 4,000 lU/mL, at least 5,000 lU/mL, at least 6,000 lU/mL, at least 7,000 lU/mL, at least 8,000 lU/mL, at least
  • the amount of the hyaluronidase administered is at least 15 IU, at least 25 IU, at least 50 IU, at least 100 IU, at least 200 IU, at least 300 IU, at least 450 IU, at least 600 IU, at least 900 IU, at least 1 ,000 IU, at least 1 ,250 IU, at least 1 ,500 IU, at least 1 ,750 IU, at least 2,000 IU, at least 3,000 IU, at least 4,000 IU, at least 5,000 IU, at least 6,000 IU, at least 7,000 IU, at least 8,000 IU, at least 9,000 IU, or at least 10,000 IU; and/or in an amount of at most 15 IU, at most 25 IU, at most 50 IU, at most 100 IU, at most 200 IU, at most 300 IU, at most 450 IU, at most 600 IU, at most 900 IU, at most 1 ,000 IU,
  • composition is administered as a single dose or in multiple doses.
  • composition is administered in a volume of at least 5 pL, at least 10 pL, at least 20 pL, at least 30 pL, at least 40 pL, at least 50 pL, at Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration least 75 mI_, at least 100 mI_, at least 200 mI_, at least 300 mI_, at least 400 m!_, or at least 500 mI_; and/or in a volume of at most 5 mI_, at most 10 mI_, at most 20 mI_, at most 30 mI_, at most 40 mI_, at most 50 mI_, at most 75 mI_, at most 100 mI_, at most 200 mI_, at most 300 mI_, at least, at least 500 mI_; and/or in a volume of at most 5 mI_, at
  • composition enters a suprachoroidal space in at most 1 minute, at most 2 minutes, at most 3 minutes, at most 4 minutes, at most 5 minutes, at most 10 minutes, at most 15 minutes, at most 30 minutes, at most 45 minutes, at most 60 minutes, at most 75 minutes or at most 90 minutes; or in about 1 minute to about 3 minutes, about 1 minute to about 5 minutes, about 1 minute to about 7 minutes, about 1 minute to about 10 minutes, about 1 minute to about 15 minutes, about 3 minutes to about 5 minutes, about 3 minutes to about 7 minutes, about 3 minutes to about 10 minutes, about 3 minutes to about 15 minutes, about 5 minutes to about 7 minutes, about 5 minutes to about 10 minutes, about 5 minutes to about 15 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 15 minutes, about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 75 minutes, about 15 minutes to about 90 minutes.
  • a composition comprising a hyaluronidase for use in reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye.
  • Use of a composition comprising a hyaluronidase for reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye.
  • Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration A composition comprising a hyaluronidase for use in the manufacture of a medicament for reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye.
  • a delivery system comprising a composition including a hyaluronidase for use in reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye.
  • a delivery system comprising a composition including a hyaluronidase for reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye.
  • a composition comprising a hyaluronidase for use in the manufacture of a medicament for reducing or eliminating a hyaluronic acid-induced blockage in the one or more blood vessels supplying blood to the eye, wherein the composition is contained in a delivery system.
  • composition comprises the hyaluronidase in a concentration of at least 15 lU/mL, at least 25 lU/mL, at least 50 lU/mL, at least 100 lU/mL, at least 200 lU/mL, at least 300 lU/mL, at least 450 lU/mL, at least 600 lU/mL, at least 900 lU/mL, at least 1 ,000 lU/mL, at least 1 ,250 lU/mL, at least 1 ,500 lU/mL, at least 1 ,750 lU/mL, at least 2,000 lU/mL, at least 3,000 lU/mL, at least 4,000 lU/mL, at least 5,000 lU/mL, at least 6,000 lU/mL, at least 7,000 lU/mL, at least 8,000 lU/mL, at least
  • the amount of hyaluronidase administered is at least 15 IU, at least 25 IU, at least 50 IU, at least 100 IU, at least 200 IU, at least 300 IU, at least 450 IU, at least 600 IU, at least 900 IU, at least 1 ,000 IU, at least 1 ,250 IU, at least 1 ,500 IU, at least 1 ,750 IU, at least 2,000 IU, at least 3,000 IU, at least 4,000 IU, or at least 5,000 IU; and/or in an amount of at most 15 IU, at most 25 IU, at most 50 IU, at most 100 IU, at most 200 IU, at most 300 IU, at most 450 IU, at most 600 IU, at most 900 IU, at most 1 ,000 IU, at most 1 ,250 IU, at most 1 ,500 IU, at most 1 ,750 IU, at most 2,000 IU, at
  • compositions are administered as a single dose or in multiple doses.
  • composition or medicament is administered in a volume of at least 5 pL, at least 10 pL, at least 20 pL, at least 30 pL, at least 40 pL, at least 50 pL, at least 75 pL, at least 100 pL, at least 200 pL, at least 300 pL, at least 400 pL, or at least 500 pL; and/or in a volume of at most 5 pL, at most 10 pL, at most 20 pL, at most 30 pL, at most 40 pL, at most 50 pL, at most 75 pL, at most 100 pL, at most 200 pL, at most 300 pL, at most 400 pL, or at most 500 pL; or in a volume of about 5 pL to about 25 pL, about 5 pL
  • composition or medicament enters a suprachoroidal space in at most 1 minute, at most 2 minutes, at most 3 minutes, at most 4 minutes, at most 5 minutes, at most 10 minutes, at most 15 minutes, at most 30 minutes, at most 45 minutes, at most 60 minutes, at most 75 minutes or at most 90 minutes; or in about 1 minute to about 3 minutes, about 1 minute to about 5 minutes, about 1 minute to about 7 minutes, about 1 minute to about 10 minutes, about 1 minute to about 15 minutes, about 3 minutes to about 5 minutes, about 3 minutes to about 7 minutes, about 3 minutes to about 10 minutes, about 3 minutes to about 15 minutes, about 5 minutes to about 7 minutes, about 5 minutes to about 10 minutes, about 5 minutes to about 15 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 15 minutes, about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 75 minutes, about 15 minutes to about 90 minutes.
  • 1 minute to about 7 minutes about 1 minute to about 10 minutes, about 1 minute to about 15 minutes, about 3 minutes to about 5 minutes, about 3 minutes to about 7 minutes, about 3 minutes to about 10 minutes, about 3 minutes to about 15 minutes, about 5 minutes to about 7 minutes, about 5 minutes to about 10 minutes, about 5 minutes to about 15 minutes, about 5 minutes to about 30 minutes, about 10 minutes to about 15 minutes, about 10 minutes to about 30 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 75 minutes, about 15 minutes to about 90 minutes.
  • kits comprising one or more containers, each container including a pharmaceutical composition including a hyaluronidase.
  • kit according to any one of embodiments 26-28, wherein the one or more containers are each a delivery system.
  • kit according to any one of embodiments 26-28, further comprising a delivery system.
  • kit according to any one of embodiments 26-30 further comprising another container including a solvent.
  • kit according to any one of embodiments 26-31 , further comprising instructions.
  • New Zealand white rabbits were used to simulate hyaluronic acid polymer associated vascular occlusive loss of vision. These animals were selected due to the similarity of their ocular vascular anatomy to that of humans.
  • New Zealand white rabbits weighing 2.0 to 3.0 kg were acclimated to the study environment for a minimum of 1 week prior to the beginning of the study. At the completion of the acclimation period, each animal was physically examined for determination of suitability for the study including examination of the skin and external ears, eyes, abdomen, neurological, behavior, and general body condition. Animals determined to be in good health were released to the study. Released animals were allocated to four group of 3 animals each with each animal uniquely identified by a cage card number.
  • an eyelid speculum was positioned on the right eye of animals who then underwent one of four treatment protocols.
  • Group 1 animals were injection controls that received no further treatment.
  • Group 2-3 animals were each administered a composition by suprachoroidal injection using a 30-gauge needle in the inferior nasal quadrant of the right eye with Group 2 animals receiving 0.1 mL of Phospho-buffered saline (PBS)(control composition), and Group 3 animals receiving 0.1 mL of a hyaluronidase (2,400 lU/mL). Animals were allowed to recover normally from the anesthetic procedure. The left eye in all animals was untreated and served as a control in these experiments.
  • PBS Phospho-buffered saline
  • OCT-A optical coherence tomography angiography
  • EMG electroretinography
  • OCT-A is a non-contact retinal imaging system that uses infrared light to image retinal vasculature and determine vascular flow changes over time.
  • OCT-A analysis to evaluate 1) pre-induction Day 0 versus post-induction Day 0 vascular flow changes; 2) pre-induction Day 0 versus post-induction Day 3 vascular flow changes; and 3) post-induction Day 0 versus post-induction Day 3 vascular flow changes.
  • ERG Full-field ERG was performed on both eyes of each animal on pre-induction Day 0 to obtain a baseline reading and on post-induction Day 3. Animals were dark adapted for at least 1 hour prior to ERG analysis. ERGs were elicited by brief flashes at 0.33 Hz delivered with a mini-ganzfeld photostimulator (Roland Instruments, Wiesbaden, Germany) at maximal intensity. Twenty responses were amplified, filtered, and averaged (Retiport Electrophysiologic Diagnostic Systems, Roland Instruments, Wiesbaden, Germany) for each animal.
  • New Zealand red rabbits will be used to simulate hyaluronic acid associated vascular occlusive loss of vision. These animals will be selected due to the similarity of their ocular vascular anatomy to that of humans. New Zealand white rabbits weighing 2.0 to 3.0 kg will be divided into groups based on the hyaluronidase dose and administration time.
  • Hyaluronic acid filler will be administered into the internal carotid artery of animals to create a central retinal artery occlusion. This artery occlusion as well as subsequent ischemia will be confirmed by both retinal fundus photography, OCT-A, and ERG analyses. Different doses of hyaluronidase will be suprachoroidally administered at several post-obstruction time points to assess both dose and timing effectiveness of the treatment. Control animals will be injected with hyaluronic acid filler in the same manner as experimental animals but will receive no hyaluronidase treatment. Fundus photography and electroretinogram changes will be recorded at 30, 60, 90, and 120 minutes after administration of hyaluronidase. Electroretinography will be performed after 60 and 120 minutes to confirm the retinal reperfusion and electrophysiologic function.
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (400 lU/mL) 5 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (400 lU/mL) 10 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (600 lU/mL) 5 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (650 lU/mL) 10 minutes after hyaluronic acid filler injection.
  • Group 1 animals receiving suprachoroidally administered 100 pL hy
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (1 ,000 ILI/mL) 5 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (1 ,000 ILI/mL) 10 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (3,000 ILI/mL) 5 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (3,000 ILI/mL) 10 minutes after hyaluronic acid filler injection.
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (10,000 lU/mL) 5 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (10,000 lU/mL) 10 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 lU/mL) 5 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 lU/mL)
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 lU/mL) 5 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 lU/mL) 10 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (20,000 lU/mL) 5 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (20,000 lU/mL) 10 minutes after hyaluronic acid filler injection.
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (400 ILI/mL) 15 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (400 ILI/mL) 30 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (650 ILI/mL) 15 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (650 ILI/mL) 30 minutes after hyaluronic acid filler injection.
  • Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidas
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (1 ,000 ILI/mL) 15 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (1 ,000 ILI/mL) 30 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (3.000 ILI/mL) 15 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (3,000 ILI/mL) 30 minutes after hyaluronic acid filler injection.
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (10,000 ILI/mL) 15 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (10,000 ILI/mL) 30 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 ILI/mL) Yoelin, Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
  • a central retinal artery occlusion will be induced by injecting 0.5 mL to 0.9 mL of hyaluronic acid filler into rabbits, which will be divided into four experimental groups each containing 2 or 3 animals with Group 1 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 lU/mL) 15 minutes after hyaluronic acid filler injection; Group 2 animals receiving suprachoroidally administered 100 pL hyaluronidase (15,000 lU/mL) 30 minutes after hyaluronic acid filler injection; Group 3 animals receiving suprachoroidally administered 100 pL hyaluronidase (20,000 lU/mL) 15 minutes after hyaluronic acid filler injection; and Group 4 animals receiving suprachoroidally administered 100 pL hyaluronidase (20,000 lU/mL) 30 minutes after hyaluronic acid filler injection.
  • the open-ended transitional phrase “comprising” (and equivalent open-ended transitional phrases thereof) includes within its meaning, as a limiting case, claimed subject matter specified by the closed-ended transitional phrases “consisting of or “consisting essentially of.”
  • the embodiments described herein or so claimed with the phrase “comprising” expressly and unambiguously provide description, enablement, and support for the phrases “consisting essentially of and “consisting of.”

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne des compositions comprenant une hyaluronidase, des dispositifs comprenant de telles compositions, ainsi que des procédés et des utilisations utilisant de telles compositions et dispositifs pour réduire ou éliminer un blocage induit par l'acide hyaluronique d'un ou plusieurs vaisseaux sanguins alimentant un œil d'un individu; des procédés et des utilisations pour utiliser de telles compositions et dispositifs pour réduire ou inhiber une occlusion vasculaire dans un œil d'un individu; et des procédés et des utilisations pour utiliser de telles compositions et dispositifs pour réduire ou inhiber une perte de vision induite par l'acide hyaluronique d'un individu.
EP21782409.3A 2020-04-02 2021-04-02 Réduction ou inhibition de lésions oculaires par administration d'hyaluronidase Pending EP4125928A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004444P 2020-04-02 2020-04-02
PCT/US2021/025668 WO2021203062A1 (fr) 2020-04-02 2021-04-02 Réduction ou inhibition de lésions oculaires par administration d'hyaluronidase

Publications (2)

Publication Number Publication Date
EP4125928A1 true EP4125928A1 (fr) 2023-02-08
EP4125928A4 EP4125928A4 (fr) 2024-06-12

Family

ID=77921064

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21782409.3A Pending EP4125928A4 (fr) 2020-04-02 2021-04-02 Réduction ou inhibition de lésions oculaires par administration d'hyaluronidase

Country Status (11)

Country Link
US (1) US11878051B2 (fr)
EP (1) EP4125928A4 (fr)
JP (1) JP2023521059A (fr)
KR (1) KR20230005198A (fr)
CN (1) CN115697348A (fr)
AU (1) AU2021248653B2 (fr)
CA (1) CA3174498A1 (fr)
IL (1) IL296979A (fr)
MX (1) MX2022012426A (fr)
WO (1) WO2021203062A1 (fr)
ZA (1) ZA202211833B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240065265A (ko) * 2021-09-25 2024-05-14 메드 프로그레스, 엘엘씨 히알루로니다제 투여를 이용한 조직 손상의 감소 또는 억제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20120101033A1 (en) 2010-10-05 2012-04-26 Shantha Totada R Retinitis pigmentosa treatment
US11076992B2 (en) 2019-04-19 2021-08-03 Elt Sight, Inc. Methods of transverse placement in ELT

Also Published As

Publication number Publication date
KR20230005198A (ko) 2023-01-09
EP4125928A4 (fr) 2024-06-12
ZA202211833B (en) 2023-04-26
AU2021248653A1 (en) 2022-12-01
AU2021248653B2 (en) 2024-05-02
CA3174498A1 (fr) 2021-10-07
JP2023521059A (ja) 2023-05-23
US20210308234A1 (en) 2021-10-07
CN115697348A (zh) 2023-02-03
WO2021203062A1 (fr) 2021-10-07
IL296979A (en) 2022-12-01
MX2022012426A (es) 2023-01-11
US11878051B2 (en) 2024-01-23

Similar Documents

Publication Publication Date Title
Voskanyan et al. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial
TW539560B (en) Ophthalmic drug delivery device
Pesando et al. Posterior chamber phakic intraocular lens (ICL) for hyperopia: ten-year follow-up
Tseng et al. A randomized clinical trial of combined topical-intracameral anesthesia in cataract surgery
AU2021248653B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
Wendt et al. Topical and intravenous pilocarpine stimulated accommodation in anesthetized rhesus monkeys
Lee et al. Anaphylactic shock caused by the epidurally-administered hyalurinidase
Blumenkranz et al. Fluid-gas exchange and photocoagulation after vitrectomy: indications, technique, and results
US11890331B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
Yeniad et al. Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases
US20240123041A1 (en) Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
CRAIG BROWN et al. Use of dilute drug solutions for routine cycloplegia and mydriasis
CN100579576C (zh) 一种防止近视发展的眼内植入材料
EP4404954A1 (fr) Réduction ou inhibition de lésion tissulaire à l'aide d'administration d'hyaluronidase
US20060034890A1 (en) Device for ocular delivery of active principles by the transpalpebral route
RU2388438C1 (ru) Способ введения лекарственных препаратов в субтеноново пространство у пациентов с оперированной рефрактерной глаукомой
Philippines et al. Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the Vitreo-Retina Society of the Philippines
RU2104679C1 (ru) Офтальмологическое лекарственное средство
Stubbs et al. Penetrating eye injury from a rigid infant pacifier
Doganay et al. Efficacy and Safety of Supraciliary Dexamethasone Implantation in Patients with Macular Edema: Preliminary and Comparative Study
Weiss Clinical Trials in Retinitis Pigmentosa Treatment
Mazza et al. Intravitreal Trimethoprim and Sulfamethoxazole Toxicity to the Retina of Albino Rabbits
SU1683740A1 (ru) Способ введени лекарственных веществ дл лечени заболеваний глаз
Kangastupa A New Platform for Suprachoroidal Drug Delivery Using Standard Commercially Available Needles
Yu et al. Retinitis pigmentosa associated with ectopia lentis in a patient with Marfan syndrome

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087526

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031704000

Ipc: A61K0038470000

A4 Supplementary search report drawn up and despatched

Effective date: 20240510

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20240503BHEP

Ipc: A61K 9/51 20060101ALI20240503BHEP

Ipc: A61K 38/47 20060101AFI20240503BHEP